Diabetes Clinical Trial
Official title:
Better Together: Leveraging Primary Care and Social Network Resources to Create a Patient-centered Approach to Improve Diabetes Among South Asians
NCT number | NCT03861546 |
Other study ID # | IRB00097724 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 3, 2019 |
Est. completion date | June 23, 2019 |
Verified date | November 2019 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to test the hypothesis that a culturally tailored lifestyle intervention can improve health behaviors among South Asians with prediabetes and diabetes
Status | Completed |
Enrollment | 14 |
Est. completion date | June 23, 2019 |
Est. primary completion date | June 23, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. age > 18 years; 2. confirmed diagnosis of prediabetes or T2D (documented A1c of = 5.7%, 2-hour post-load glucose of >140, or FBG of >100); 3. a family member or peer willing to participate and attend all sessions as a social influencer; 4. proficiency in English of at least one member of each dyad, 5. willingness to provide written consent. Exclusion Criteria: 1. type 1 diabetes or diabetes secondary to other conditions (e.g. steroid-induced, pancreatic insufficiency, or chemotherapy-induced); 2. malignancy or life-threatening illness with life expectancy of <5 years; 3. end-stage disease or serious illness that prohibits participation (e.g. end-stage renal disease or class IV congestive heart failure); 4. inability to perform unsupervised physical activity; 5. pregnancy; 6. diagnosed cognitive deficits or limited decision-making capacity; 7. alcohol or substance abuse; 8. homelessness or no fixed address. |
Country | Name | City | State |
---|---|---|---|
United States | Emory Family Medicine Clinic | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Participant perceptions of SMA program | Physician-participants interviews will be digitally audio-recorded and transcribed verbatim, with de-identified transcripts analyzed. | 4 months | |
Primary | SMA program retention rate | Number of participants retained will be recorded and SMA retention rate will be calculated | 4 months | |
Secondary | Change in body mass index (BMI) | Body Mass Index (BMI) is a number representing person's weight in kilograms divided by the square of height in meters. A high BMI can be an indicator of high body fatness. | Baseline, 4 months, and 12 months | |
Secondary | Change in blood pressure | Blood pressure will be measured pre- and post- intervention | Baseline, 4 months, and 12 months | |
Secondary | Change in blood cholesterol level | Cholesterol level will be measured by blood test pre- and post- intervention | Baseline, 4 months, and 12 months | |
Secondary | Change in physical activity daily minutes | Daily minutes of moderate intensity exercise will be self reported by participants | Baseline, 4 months, and 12 months | |
Secondary | Change in step counts | Daily step counts (using wearable perdometer) will be recorded. | Baseline, 4 months, and 12 months | |
Secondary | Change in diet | Pre-post assessment of change in consumption will be done using food frequency questionnaire. It has 16 questions that assess dietary habits over the past week. | Baseline, 4 months, and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |